ArticleJournal of gastrointestinal oncology2011
The role of radiotherapy in management of pancreatic cancer.
Article in Journal of gastrointestinal oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis.Radiation oncology (London, England) · 2015Trial
- Pancreatic SBRT on four modern platforms: dosimetric and radiobiological gains with the Ethos ring-gantry linac versus TrueBeam, Halcyon, and helical tomotherapy.Radiation oncology (London, England) · 2026Article
- Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.Current pharmaceutical design · 2025Review
- Pancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatment.Frontiers in oncology · 2023Review
- Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach.World journal of clinical oncology · 2020Article
- Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- Review
- Markerless Pancreatic Tumor Target Localization Enabled By Deep Learning.International journal of radiation oncology, biology, physics · 2019Article
- Variation in accumulated dose of volumetric-modulated arc therapy for pancreatic cancer due to different beam starting phases.Journal of applied clinical medical physics · 2019Article
- Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.The oncologist · 2019Article
- OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling.Oncotarget · 2017Article
- Article
- Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice.Gastroenterology · 2016Article
- Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.Journal of gastrointestinal oncology · 2016Review
- A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer.Gut and liver · 2016Article
- Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma.Przeglad gastroenterologiczny · 2016Review
- Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2015Article
- Novel strategies for managing pancreatic cancer.World journal of gastroenterology · 2014Review
- Adjuvant therapy in pancreatic cancer.World journal of gastroenterology · 2014Review
- The role ofJournal of radiation oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the leading causes of cancer death. The treatment options in pancreatic cancer remain limited. This review provides an overview of the role of radiotherapy (RT) alone or in combination with systemic treatment at different settings of treatment strategy. Neoadjuvant chemoradiotherapy (CRT) may downstage the borderline resectable disease and make resection possible, which could translate to a survival benefit. Although the benefit of adjuvant CRT remains controversial due to inconsistent outcome of randomized trials, in North America it is still a common recommendation of the treatment. For locally advanced pancreatic cancer, the treatment option could either be chemotherapy or chemoradiotherapy. By using advanced radiotherapy modalities, the toxicity of RT could be reduced and RT dose escalation becomes possible to improve locoregional control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.